Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg

Touret, Franck; Martin‐Blondel, Guillaume; Lamballerie, Xavier De; Dupont, Axelle; Izopet, Jacques; Mentré, France; Kamar, Nassim; Autran, Brigitte; Paintaud, Gilles; Caillard, Sophie; Richez, Christophe; Couzi, Lionel; Xhaard, Aliénor; Marjanovic, Zora; Avouac, Jérôme; Jacquet, Caroline; Anglicheau, Dany; Cheminant, Morgane; Yazdanpanah, Yazdan; N’Guyen, Stéphanie; Terrier, Benjamin; Gottenberg, Jacques Éric; Besson, Caroline; Letrou, Sophie; Kali, Sabrina; Angoulvant, Denis; Barthélémy, Karine; Priet, Stéphane; Nurtop, Elif; Sanchez, Ventzislava Petrov; Tardivon, Coralie; Blancho, Gilles; Bourgeois, Amandine Le; Lévy, Vincent

doi:10.1016/j.jinf.2023.02.002

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Zhao et al observed that XBB.1.5 showed the greatest escape activity among the subvariants [ 22 ], and the experiments with pseudoviruses harboring SARS-CoV-2 spike proteins of BA.5, XBB.1.5, and XBB.1.16 produced similar results [ 23 ]. Other studies demonstrated that Evusheld has lost antiviral efficacy against XBB subvariants and BQ.1.1 [ 24 , 25 , 26 ]. To the best of our knowledge, no data are available in the literature about the serum neutralization or in vitro activity of Evusheld against the EG.5 strain.…”

Section: Discussionmentioning

confidence: 99%

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Gidari,

Sabbatini,

Bastianelli

et al. 2024

Viruses

View full text Add to dashboard Cite

Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro. Study design: Conducted in Italy, this research involves immunocompromised patients who received Evusheld. It evaluates serum neutralization activity against different SARS-CoV-2 strains (20A.EU1, BA.5, BQ.1, XBB.1.5, XBB.1.16, and EG.5) before (T0), after 14 (T1), and after 30 (T2) days from the tixagevimab/cilgavimab injection. Furthermore, the in vitro activity of Evusheld against SARS-CoV-2 VOCs was evaluated. Results: The cohort was composed of 72 immunocompromised patients. The serum neutralizing activity of tixagevimab/cilgavimab-treated patients was notably lower against newer variants such as BQ.1, XBB.1.5, XBB.1.16, and EG.5. Then, the in vitro study detailed specific EC50 values to quantify the activity of tixagevimab/cilgavimab against various SARS-CoV-2 VOCs. Newer variants like BQ.1 and XBB.1.5 exhibited notably lower neutralization, underscoring the challenges in effectively countering the evolving virus. Interestingly, tixagevimab/cilgavimab maintained reduced but still valid activity against EG.5 with an EC50 of 189 ng/mL and Cmax/EC90 of 110.7. Conclusions: Tixagevimab/cilgavimab efficacy wanes against novel subvariants. This underscores the critical need for ongoing adaptation and vigilance in prophylactic strategies to effectively counter the dynamic and unpredictable nature of the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Gidari,

Sabbatini,

Bastianelli

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…Medical practitioners have showcased the ability of this drug to reduce the risk of SARS-CoV-2 infection during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves in unvaccinated individuals ( 48 , 49 ). Following the emergence of the Omicron variant and its sub-lineages, tixagevimab/cilgavimab was recognized as the sole effective monoclonal combination therapy available ( 50 ), with neutralizing activity against the Omicron variant sub-lineages BA.1 and BA.1.1 ( 51 )as well as against sub-lineages BA.2 and BA.5 ( 49 ).…”

Section: Application Of Monoclonal Antibodies For Treating Ktrs Infec...mentioning

confidence: 99%

Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19

Zheng,

Sun,

et al. 2024

Front. Med.

View full text Add to dashboard Cite

The sudden outbreak of coronavirus disease 2019 (COVID-19) in early 2020 posed a massive threat to human life and caused an economic upheaval worldwide. Kidney transplant recipients (KTRs) became susceptible to infection during the COVID-19 pandemic owing to their use of immunosuppressants, resulting in increased hospitalization and mortality rates. Although the current epidemic situation is alleviated, the long-term existence of COVID-19 still seriously threatens the life and health of KTRs with low immunity. The Omicron variant, a highly infectious but less-pathogenic strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised concerns among transplant physicians regarding managing KTRs diagnosed with this variant. However, currently, there are no clear and unified guidelines for caring for KTRs infected with this variant. Therefore, we aimed to summarize the ongoing research on drugs that can treat Omicron variant infections in KTRs and explore the potential of adjusting immunotherapy strategies to enhance their responsiveness to vaccines. Herein, we discuss the situation of KTRs since the emergence of COVID-19 and focus on various prevention and treatment strategies for KTRs since the Omicron variant outbreak. We hope to assist physicians in managing KTRs in the presence of long-term COVID-19 variants.

show abstract

“…Such modifications of antibody structure to increase their persistence along time were, in part, reported in 2009 4 and were applied in 2013 5 to motavizumab, an antibody directed against the respiratory syncytial virus fusion protein. Although the protection provided by Tix‐Cil was evidenced 6 against pre‐Omicron SARS‐CoV‐2 variants, Omicron and its sub‐variants developed progressive immune escape from these ViMABs (at first tixagevimab and then cilgavimab), which led to discontinue their use as prophylactic or curative agent in January 2023 in France 7 . However, apart against SARS‐CoV‐2, other antibodies with prolonged half‐lives have been developed, in particular against HIV, 8 Marburg virus, 9 Venezuelan equine encephalitis virus, 10 and an anti‐respiratory syncytial virus ViMAb, nirsevimab, has recently received a European market authorization 11 .…”

Section: N = 147mentioning

confidence: 99%

“…Although the protection provided by Tix-Cil was evidenced 6 against pre-Omicron SARS-CoV-2 variants, Omi-cron and its sub-variants developed progressive immune escape from these ViMABs (at first tixagevimab and then cilgavimab), which led to discontinue their use as prophylactic or curative agent in January 2023 in France. 7 However, apart against SARS-CoV-2, other antibodies with prolonged half-lives have been developed, in particular against HIV, 8 Marburg virus, 9 Venezuelan equine encephalitis virus, 10 and an anti-respiratory syncytial virus ViMAb, nirsevimab, has recently received a European market authorization. 11 It is therefore important to assess the kinetics of such antibodies in real-life conditions.…”

mentioning

confidence: 99%

Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients

Perrier,

Lupo,

Epaulard

2023

Transplant Infectious Dis

View full text Add to dashboard Cite

Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg

Cited by 7 publications

References 7 publications

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19

Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients

Contact Info

Product

Resources

About